Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)

NCT04855721 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.

NCT NCT04855721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
Lead sponsor
Aurigene Discovery Technologies Limited
Phase
Phase 2
Overall status
Completed
Start date
May 4, 2021
Completion date
December 10, 2022
Enrollment
141 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis